Dr. Kathy High, President and Head of Research and Development, and Federico Mingozzi, Chief Scientific Officer, in the Spark Therapeutics laboratory
Research scientists in the Spark Therapeutics laboratory
Dr. Kathy High, President and Head of Research and Development, and Federico Mingozzi, Chief Scientific Officer, in the Spark Therapeutics laboratory
Employees in the Spark Therapeutics office

We don’t follow footsteps. We create the path.

News & events

Definitive Merger Agreement with Roche Deal expected close in Q2 2019; Spark Therapeutics to continue operations in Philadelphia as an independent company within the Roche Group

Read More read more

2018 Earnings Spark Therapeutics reports 2018 financial results and recent business progress

Read More read more

Hemophilia A Data Update Updated data presented on Phase 1/2 clinical trial of SPK-8011 in hemophilia A at ASH

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia, and neurodegenerative diseases.

Learn More